Agree on both counts it was probably undervalued (when it was in the 3 range) and is quite volatile in price though I don't know about "settling down in the 6's".
They touted patients continuing on therapy in open label extensions of past trials for some time so I don't make anything out of that.
I currently have no position. I don't see Fabry as enough to get them to profitability.